India needs to Ramp up Production of Hydroxychloroquine to Meet Demand

As per India Pharma Industry, India does 70 percent of the world’s production of Hydroxychloroquine. There is enough stock that lies in the country. If the need arises, big drug firms are ready to ramp up production quickly. It will help to meet local as well as export demand.

On March 25, India had banned the export of Hydroxychloroquine (HCQ). The objective was to minimize speculative buying and hoarding of the drug. The drug could successfully be used to fight coronavirus infection.

India lifted the ban on Hydroxychloroquine, which is an anti-malarial drug. It is touted as ‘game-changer’ to treat COVID-19 patients. It happened after Trump requested to release stock of the medicines.

‘To meet, both the domestic and export demand for paracetamol and Hydroxychloroquine is a big target for us in such tough scenarios.’ Indian Pharmaceutical Alliance’s Secretary-General stated. Recently, the Ministry of Health and Family Welfare placed an order for around ten crore pills of HCQ. It can potentially treat over 71 lakh people. However, the production of Hydroxychloroquine is a challenge.

  • Health Experts severely restrict excessive use of such drugs. For the treatment of COVID-19 patients due to its anti-viral properties, the drug has its usage.
  • Indian Council of Medical Research recommended the use of Hydroxychloroquine as a preventive medication for COVID-19 Patients. The drug is also advisable for the healthcare workers involved in the treatment of the coronavirus pandemic and is at high-risk. Each COVID-19 patient suffering from the disease needs to complete a 14-tablet course.

Indian Drug Manufacturer’s Association (IDMA), Executive Director Ashok Kumar Madan, stated that there are about 24 million tablets per year production of Hydroxychloroquine. It helps to deal with the three diseases – malaria, rheumatoid arthritis, and lupus.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.